Table 3. Chi-squared analysis of contingency table between TTN/TP53 mutation and anatomic neoplasm subdivision of LUAD and LUSC patients receiving chemotherapy.
| Therapeutic response | Anatomic neoplasm subdivision | Anatomic neoplasm subdivision | |||||
|---|---|---|---|---|---|---|---|
| LUAD | P value | LUSC | P value | ||||
| Upper | Lower | Upper | Lower | ||||
| TTN+/TP53+ | |||||||
| Response | 19 | 5 | 0.0025** | 29 | 11 | 0.0216* | |
| No response | 2 | 7 | 11 | 14 | |||
| TTN+/TP53– | |||||||
| Response | 11 | 5 | 0.7429 | 13 | 4 | 0.0368* | |
| No response | 14 | 8 | 8 | 11 | |||
| TTN–/TP53+ | |||||||
| Response | 9 | 5 | 0.5229 | 2 | 3 | 0.3451 | |
| No response | 12 | 4 | 9 | 5 | |||
“+” indicates MT; “–” indicates WT. *, P<0.05; **, P<0.01. TTN, titin; TP53, tumor protein 53; LUAD, lung adenocarcinoma; LUSC, lung squamous carcinoma; MT, mutant-type; WT, wild-type.